Ascletis Initiates Phase IIa Study for ASC30
- The first participants in a U.S. Phase IIa trial focused on treating obesity or overweight with the small molecule oral GLP-1 receptor agonist ASC30 have been dosed. This trial is vital in evaluating ASC30's efficacy for those with at least one weight-related comorbidity.
Overview of the ASC30 Trial
- ASC30, administered as a once-daily oral tablet, showed promising results in previous studies, highlighting a potential mean body weight reduction of 6.5% after four weeks of treatment.
- Data from the ongoing Phase IIa study are expected to be released in the fourth quarter of 2025, which underlines the company’s commitment to advancing obesity treatment.
Details of the Study's Design
- This 13-week Phase IIa study is a randomized, double-blind, placebo-controlled, multi-center trial intended to assess the safety, efficacy, and tolerability of ASC30 in individuals with varying degrees of obesity or overweight. Participants are categorized based on body mass index (BMI) criteria, ensuring a structured approach to understanding ASC30's effects.
- Two formulations of ASC30 will be evaluated: formulation 1 (ASC30 tablets) and formulation 2 (ASC30 tablets A1). The primary outcome will focus on the percentage change in body weight from the baseline at Week 13, which facilitates a comprehensive evaluation of the drug's impact.
Understanding ASC30's Mechanism
- ASC30 was developed in-house by Ascletis, claiming its place as a unique investigational small molecule GLP-1 receptor biased agonist. This class of drugs mimics the action of incretin hormones, which play essential roles in insulin regulation and appetite control, making ASC30 potentially effective for weight management.
- Ascletis is optimistic about ASC30, which not only aims for once-daily oral administration but also has possibilities for once-monthly subcutaneous injections, offering a variety of treatment options for patients.
Looking Ahead
- The founder and CEO of Ascletis, Jinzi Jason Wu, expressed enthusiasm about the trial's progress, stating that they are ahead of schedule with participant screenings already completed and initial dosing underway. This proactive approach could lead to valuable data in due course.
About the Company
- Ascletis Pharma Inc. is dedicated to developing cutting-edge therapeutics for metabolic diseases. Backed by its advanced Artificial Intelligence-Assisted Structure-Based Drug Discovery (AISBDD) platform, Ascletis has successfully brought several promising drug candidates through its pipeline. Positioned on the Hong Kong Stock Exchange, the company aims to continue its innovative journey in the field of biotechnology.
Frequently Asked Questions
What is the purpose of the ASC30 Phase IIa study?
The purpose of the ASC30 Phase IIa study is to evaluate the efficacy, safety, and tolerability of ASC30 in individuals with obesity or overweight.
What are the expected outcomes of the trial?
Topline data from the trial is expected to provide insights into the mean percentage body weight change from baseline after 13 weeks.
Who is participating in the study?
Participants include those with obesity or overweight who have at least one weight-related comorbidity, ensuring a targeted evaluation.
What makes ASC30 unique?
ASC30 is designed as a first investigational small molecule GLP-1 receptor biased agonist that can be administered both orally and via subcutaneous injection.
How does Ascletis support drug development?
Ascletis utilizes sophisticated platforms for drug discovery, focusing on innovative therapeutics aimed at treating metabolic diseases.
